Detector Labels and Bioconjugation in Lateral Flow Assays
- 1 day ago
- 9 min read
(8-10 Minutes)
Just as careful antibody selection is critical for Lateral Flow Assay (LFA) performance, the choice of detector label and its conjugation strategy directly influences assay sensitivity, specificity, reproducibility and scalability. Detector labels convert binding events into measurable signals and the way these labels are prepared and evaluated has a profound impact on how reliably an assay performs.
Gold nanoparticles have become the most widely used detector because of their strong optical properties, ease of visual interpretation and relatively straightforward conjugation chemistry. Their surface can readily support antibody binding through well understood passive adsorption or covalent coupling methods, giving developers flexibility in how conjugates are prepared.
Passive adsorption, which relies on pH and charge dependent interactions between antibodies and particle surfaces, remains common because it is simple and rapid. Alternately, covalent attachment techniques, often using activated carboxyl surfaces and carbodiimide chemistry, can create more stable and controllable conjugates, particularly useful in demanding matrices such as urine or saliva.
While gold remains the standard label for lateral flow assays, alternative labels such as fluorescent, latex and magnetic particles are also employed where enhanced sensitivity, multiplexing or particular bespoke strategies are desired. Differently coloured latex particles are especially useful for multiplex assays, as distinct colours can be assigned to different targets, allowing simultaneous visual discrimination without specialised instrumentation. Fluorescent particles can generate strong signals and are well suited to reader-based detection, facilitating quantitative analysis where required. Magnetic particles may further enhance assay performance by enabling signal generation throughout the membrane rather than being confined to the surface. Importantly, quantitative measurement is achievable with several label types, including gold when paired with an appropriate reader.
Regardless of the label used, improvements in analytical sensitivity are most effectively realised when combined with high-quality antibodies and well-controlled conjugation, ensuring a robust assay foundation.
Conjugation and Particle Considerations
Colloid Quality and Particle Uniformity
A robust conjugation strategy depends not only on the biological component but also on the physicochemical properties of the particle. The colloid itself is foundational; nanoparticles should be highly homogeneous and monodispersed. Narrow size distributions reduce batch-to-batch variability, support consistent optical performance and promote predictable membrane migration, while polydispersity or irregular morphology can compromise antibody loading, flow and assay reproducibility.
Particle size and uniformity can be assessed by transmission electron microscopy (TEM), which provides core diameter, morphology and coefficient of variation (%CV) or by dynamic light scattering (DLS), which gives hydrodynamic size and polydispersity index (PDI). Well-dispersed colloids typically show a PDI ≤ 0.2 by DLS, while high-quality citrate gold colloids often exhibit TEM size CV ≤ 10%.
Optical density (OD), measured at the plasmon resonance wavelength, provides a rapid indication of particle concentration, batch consistency and potential aggregation. Zeta potential, determined via electrophoretic mobility, reflects surface charge and electrostatic stability. For citrate-stabilised gold, zeta potentials are typically negative (−25 to −40 mV) under low ionic strength, indicating good stability, though it remains sensitive to buffer composition and pH.
The choice of characterisation method depends on supplier specifications and application needs; together, these measurements guide assessment of colloidal quality and suitability for conjugation and assay development.
Particle Size and Material Properties
Particle size and material properties influence assay performance. Smaller particles generally provide a higher surface-area-to-volume ratio, allowing for dense conjugation of antibodies or ligands, while larger particles produce stronger visual or optical signals but may migrate more slowly and be more prone to aggregation.
For dye-loaded latex, the colour comes from internal dye saturation rather than plasmonic scattering, allowing both high surface area and bright signal intensity to be achieved simultaneously. This enables optimisation of antibody density and visual or optical output independently of particle size.
Ultimately, particle size, uniformity, surface chemistry and optical properties should all be considered together to balance conjugation efficiency, flow characteristics and signal detectability in lateral flow assays.
Antibody Loading and Surface Presentation
Antibody loading must be carefully optimised so that sufficient binding sites are presented without over-crowding the particle surface. Excess antibody can promote instability through bridging or steric hindrance, whereas insufficient coverage may leave exposed particle surface prone to non-specific interactions. Antibody presentation at the particle interface, including surface density and orientation, influences both antigen accessibility and colloidal stability.
Conjugation pH is also critical, as it determines the net charge of both antibody and particle surface, affecting adsorption strength, orientation and aggregation risk. Tight control of buffer composition and pH during conjugation therefore improves functional performance and batch reproducibility.
Blocking and Stabilisation Strategy
After antibody adsorption, residual surface sites should be stabilised using high-purity, reproducible blocking agents such as BSA and casein. The consistency and grade of these materials influence background signal, conjugate stability and long-term storage performance.
Variability in blocker composition can introduce unintended assay noise or reduce stability, particularly at scale. Well characterised blockers, together with controlled surfactant levels, help maintain dispersion and promote smooth migration along the membrane while minimising non-specific binding.
Conjugation Strategies Beyond Passive Adsorption
In addition to passive adsorption, antibodies can be covalently attached to particles using chemistries such as EDC/NHS activation (linking carboxyl groups on the particle to antibody amines), thiol-maleimide coupling (targeting engineered cysteines for directional attachment), or click chemistry (e.g. strain-promoted azide-alkyne cycloaddition for precise, bioorthogonal conjugation).
These approaches provide more controlled and predictable attachment compared with electrostatic adsorption, which can be influenced by particle surface charge, pH or ionic conditions.
Advantages of covalent attachment include:
Controlled orientation: By targeting specific regions of the antibody (e.g. Fc vs Fab), covalent attachment can orient antigen-binding domains outward, improving accessibility to the target and potentially enhancing assay sensitivity. This reduces steric hindrance and promotes more uniform binding interactions compared with passive adsorption.
Enhanced stability: Covalent bonds are chemically stronger than the weak electrostatic or hydrophobic forces used in passive adsorption. This reduces the risk of antibody desorption during storage, drying or assay flow, particularly in complex sample matrices.
Reproducibility and scale-up: Once optimised, covalent attachment is less sensitive to minor variations in particle charge or buffer conditions than passive adsorption, supporting consistent batch-to-batch performance and scaling from laboratory development to larger manufacturing runs.
Practical considerations:
Despite these advantages, covalent conjugation requires careful control of reaction conditions, including pH, buffer composition, temperature and stoichiometry. Monitoring these parameters is essential not only for reproducibility but also to preserve antibody functionality, as improper conditions can lead to denaturation, aggregation or loss of antigen-binding activity. With careful optimisation and expertise in bioconjugation, covalent conjugates can remain stable, active and consistent across multiple batches.
Quality Control Techniques in Practice
Quality control during conjugate preparation is a combination of complementary checks that together provide a reliable picture of conjugate behaviour. Some of the common and practical QC approaches include:
Optical evaluation: Simple observation of colour and absorbance spectra can quickly indicate whether a nanoparticle suspension is monodispersed or has aggregated. Gold nanoparticles that maintain their characteristic red colour are more likely to be stable and functional, while shifts toward purple or broadening of the absorption peak can signal issues. These checks are often the first indication that conjugation conditions, pH adjustment or blocking efficiency require optimisation. Where appropriate, particle sizing methods such as DLS can provide additional confirmation of size distribution and dispersion, particularly during process transfer or scale-up.
Dispersed 40 nm gold nanoparticles appear red due to a localised surface plasmon resonance (LSPR) peak at ~525–535 nm. Upon aggregation, plasmon coupling causes a red-shift and band broadening (typically ~600–700 nm), turning the solution blue or purple. Extensive aggregation leads to precipitation, leaving a clear solution with black solids. Salt challenge tests: The stability of antibody–particle conjugates can also be evaluated by exposing the colloid to increased ionic strength, commonly using NaCl or other salts. Aggregation induced by salt indicates insufficient antibody coverage or suboptimal blocking, as the electrostatic repulsion that normally stabilises the colloid is screened. Gold nanoparticles that remain red and dispersed under these conditions demonstrate robust surface coverage and stability, providing confidence that conjugates will perform reliably under assay conditions.
Surface Immunoreactivity Assessment: Early-stage functional checks complement optical and colloidal assessments and help prevent unnecessary use of valuable antigen materials. A common first step is to confirm that the antibody has successfully conjugated to the particle surface using a half-strip or partial dipstick with an anti-species capture line. For example, a mouse monoclonal conjugate can be tested on a membrane striped with goat anti-mouse IgG (GAM). A clear signal confirms successful conjugation, while weak or inconsistent signal indicates suboptimal conjugation conditions, such as incorrect pH, insufficient antibody loading, over-blocking or particle instability.
Target Antigen Functional Assessment: Once conjugates have passed optical and surface immunoreactivity screening, their functional reactivity with the intended target antigen must be assessed. This step confirms that antibody activity has been preserved during conjugation and that the conjugate generates an appropriate response under assay relevant conditions. Testing is typically performed using full or partial LFA strips with known concentrations of the target antigen.
Key considerations during antigen testing include ensuring consistent flow, minimising background signal and confirming that the observed response corresponds to the analyte rather than non-specific interactions. Signal intensity should be interpreted relative to background levels, with signal-to-noise ratio used as a key comparative metric across batches. Conjugates producing moderate signal with low background may demonstrate superior overall performance compared with higher-signal preparations exhibiting increased non-specific binding. Comparing results across replicate strips or batches helps identify any variability introduced during conjugation or storage. This stage is critical for establishing acceptance criteria for final conjugate use and provides a direct measure of how well the conjugate performs in the context of the intended assay.
Ongoing Stability Monitoring: In addition to initial optical and functional checks, conjugates should be monitored for stability over time. Measuring absorbance provides rapid insight into aggregation, while DLS or other particle sizing methods confirm that monodispersity is maintained. Tracking these parameters during storage helps ensure that particle integrity is preserved. Periodic functional checks can provide additional assurance that antibody activity remains consistent over the product’s shelf life.
These QC steps emphasise function over form, ensuring that particles and antibodies not only appear stable but behave predictably in the context of the assay, the ultimate test of conjugate quality.
Integrating Conjugates into LFA Development
Once conjugates have been prepared, characterised and quality checked, they must be carefully integrated into the lateral flow assay to ensure optimal flow, signal intensity and reproducibility. A key part of this stage is formulation of the conjugate release system. Drying buffers are commonly supplemented with stabilising sugars such as sucrose or trehalose, which help preserve particle integrity during drying and facilitate rapid, complete rehydration on the strip.
Pad selection and preparation also strongly influence conjugate release and assay performance. Conjugate pads must balance rapid wetting and release with compatibility with the sample matrix, which may vary widely in viscosity, ionic strength or pH. Pre-treatment buffers can be applied to adjust pH or ionic conditions for challenging matrices such as urine or saliva, preventing premature conjugate collapse or aggregation. These buffers frequently contain carefully optimised levels of non-ionic surfactants such as Tween 20, which enhance pad wetting, improve conjugate mobilisation and minimise aggregation or non-specific binding under complex matrix conditions.
Conjugate Drying and Titration
Temperature, humidity and drying duration require optimisation to stabilise conjugates without compromising antibody activity. Similarly, the amount of conjugate applied to the pad (“number of gold units” or particle load) is typically titrated to achieve strong detectable signal whilst minimising background noise or conjugate clearance issues. Titrating the conjugate is also important in avoiding phenomena such as the hook effect at high analyte concentrations. Iterative testing across a range of conjugate loads, pad treatments and drying formulations is necessary to identify the combination that provides robust signal intensity, reproducible flow and consistent sensitivity across batches.
It is important to recognise that conjugate behaviour may change when transitioning from liquid format testing to dried conjugate formats. A reduction in apparent sensitivity can occur following dry down due to reduced mixing time between the conjugate and antigen during lateral flow, as well as subtle effects on antibody activity, particle dispersibility or conjugate mobility on the membrane. To obtain a realistic assessment of performance, it is recommended that conjugates be evaluated in their dried format prior to final selection.
Early Matrix Evaluation
Finally, early testing of conjugates in relevant sample matrices is critical. Plasma, urine, saliva or other biological fluids contain proteins, salts, enzymes and endogenous binding components that can significantly alter flow dynamics, affect antibody–antigen interactions, destabilise conjugates or increase background signal. Performance observed in buffered systems may not reflect behaviour in complex clinical matrices. Evaluating conjugates under realistic sample conditions at an early stage enables identification of matrix effects, interference risks and stability limitations before scale-up.
Integrating antibody performance, particle quality, conjugation chemistry, stabilising formulations and functional testing within the intended matrix ensures that LFAs are not only analytically sensitive, but also robust, reproducible and reliable from prototype development through manufacturing and real-world use.
Conclusion
Detector labels and conjugation strategies are critical to LFA performance, complementing antibody selection and assay design. High-quality colloids, carefully optimised conjugation and effective stabilisation together improve assay sensitivity, specificity, and reproducibility.
Expertise in bioconjugation spanning multiple chemistries such as passive adsorption, covalent coupling and directional attachment can be applied to a variety of particle types, including gold, latex, fluorescent and magnetic labels. Ensuring conjugate quality through optical evaluation, functional testing and stability assessments confirms predictable behaviour in the assay, while careful integration with pad formulation, drying conditions and relevant sample matrices supports consistent flow, signal and robustness.
Expertise in both bioconjugation and LFA development enables developers to maximise assay performance, even in challenging matrices or when pushing the limits of sensitivity.
Click here to learn more about our lateral flow conjugation services or contact us to speak to our team about your assay development needs.
Comments